Related Experiment Video
Updated: May 19, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Challenges in atrial fibrillation
Ron Pisters1, Hugo Ten Cate, Harry J Crijns
1Department of Cardiolog, Maastricht University Medical Centre, Maastricht, The Netherlands. r.pisters@mumc.nl
Insights
Managing atrial fibrillation (AF) requires careful antithrombotic therapy. This review focuses on antiplatelet agents, stroke, and bleeding risk assessment in AF patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation (AF) is a common chronic heart condition.
- Managing AF is complex due to associated heart diseases.
- Antithrombotic therapy in AF presents significant challenges.
Purpose of the Study:
- To review the current use of antiplatelet agents in AF management.
- To address challenges in assessing stroke and bleeding risks.
- To explore novel antithrombotic agents for future AF treatment.
Main Methods:
- Literature review of current guidelines and clinical tools.
- Analysis of antiplatelet agent efficacy and safety in AF.
- Discussion of risk stratification models for stroke and bleeding.
- Exploration of emerging antithrombotic therapies.
Main Results:
- Current antiplatelet strategies require careful risk-benefit assessment.
- Clinical tools exist for evaluating stroke and bleeding risks.
- Novel agents may offer improved antithrombotic management in AF.
Conclusions:
- Optimizing antithrombotic therapy in AF is crucial.
- Accurate risk assessment is key for antiplatelet agent selection.
- Future research should focus on personalized antithrombotic approaches in AF.
Abstract:
Atrial fibrillation (AF) is an extremely prevalent dynamic chronic disease often associated with underlying heart disease, making the management of AF challenging. The antithrombotic management - and in particular the use of antiplatelet agents herein - is challenging as it depends on the (adequate) assessment of the risk of stroke and major bleeding. We therefore focus on the current (recommended) use of antiplatelet agents, address the caveats, and provide clinical tools to assess risk of stroke and major bleeding. Furthermore, we discuss novel antithrombotic agents to provide a future perspective of the role of antiplatelet agents in the antithrombotic management of AF patients.
Related Concept Videos
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmias III: Characteristics of Dysrhythmias
Dysrhythmias II: Classification of Tachyarrhythmias
Dysrhythmias IV: Characteristics of Bradyarrhythmias

